Akston Biosciences

Risk score

57

Headquarters

Flag of United States of AmericaUnited States of America

Situated in Beverly, Massachusetts, Akston Biosciences utilizes its fundamental proficiency in creating innovative amalgamated proteins to produce and fabricate novel categories of biological treatments for Type 1 diabetes (T1D) prevention, extended-acting insulin therapy, and vaccines. Established by the team responsible for pioneering the world’s first clinical glucose-responsive insulin at SmartCells, Inc. (acquired by Merck & Co. in 2010), Akston has secured more than $18 million in equity funding from the management team and private investors, in addition to $10 million from National Institutes of Health grants and The Helmsley Charitable Trust.